{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:37:54Z","timestamp":1771850274698,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jacc.2023.06.022","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T07:32:51Z","timestamp":1693121571000},"page":"1092-1095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initiating Mineralocorticoid Antagonists for Longstanding Heart\u00a0Failure With Reduced Ejection Fraction"],"prefix":"10.1016","volume":"82","author":[{"given":"Andrew J.","family":"Sauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.06.022_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.06.022_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.06.022_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.06.022_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get With The Guidelines\u2014Heart\u00a0Failure Registry","volume":"8(7)","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.06.022_bib5","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/eurheartj\/ehad169","article-title":"Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?","volume":"22","author":"Sherrod","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.06.022_bib6","article-title":"Better: A Surgeon\u2019s Notes on Performance","author":"Gawande","year":"2008","journal-title":"Picador"},{"key":"10.1016\/j.jacc.2023.06.022_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jacc.2023.06.021","article-title":"Underutilization of mineralocorticoid antagonists in patients with heart failure and reduced ejection fraction","volume":"82","author":"Matsumoto","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.06.022_bib8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cardfail.2022.05.014","article-title":"Can we stop reflexively discontinuing mineralocorticoid antagonists for patients with heart failure and hyperkalemia?","volume":"28","author":"Mastoris","year":"2022","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2023.06.022_bib9","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.06.022_bib10","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2023.06.022_bib11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A\u00a0randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2023.06.022_bib12","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.06.022_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723060746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723060746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:15:15Z","timestamp":1738934115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723060746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0735109723060746"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.06.022","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiating Mineralocorticoid Antagonists for Longstanding Heart\u00a0Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.06.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}